摘要
在近20年,小分子核糖核酸(miRNAs)成为了人类癌症中诊断和判断预后的最具前途阶级的生物标志物。从治疗的角度来看,在病理学进展中认识小分子核糖核酸中分子的角色,对新的治疗方法的选择产生了重大影响。此外,内在特性赋予了小分子核糖核酸在体外实验的稳定,耐受更长的体内分子/结构阻力和活动。单独或结合当前的靶向疗法的临床前模型一直强调基于小分子核糖核酸在治疗中的可行性和有效性。这种治疗方法的吸引强度取决于小分子核糖核酸目前多基因靶向的能力,通常在一种特定背景下的网络和路径。此属性允许基于小分子核糖核酸的治疗在调节不同的生物过程正常细胞稳态和病理相关是十分有效的。本综述的目的是总结小分子核糖核酸在胃肠道肿瘤中的作用及其作为新的生物标志物和治疗的潜在用途。
关键词: 生物标志物,胃肠道癌变,锁核酸,小分子核糖核酸,非编码核糖核酸,疗法。
Current Drug Targets
Title:MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Volume: 16 Issue: 4
关键词: 生物标志物,胃肠道癌变,锁核酸,小分子核糖核酸,非编码核糖核酸,疗法。
摘要: In the last 20 years, microRNAs (miRNAs) have become the most promising class of diagnostic and prognostic biomarkers for human cancer. From a therapeutic perspective, advances in the understanding of the molecular role of miRNAs in the pathological processes have significantly influenced the selection of new therapeutic modalities. Moreover, the intrinsic characteristics that confer stability to miRNAs in vitro, allow a longer molecular/structural resistance and activity in vivo. Preclinical models have consistently underlined the feasibility and efficacy of miRNA-based therapies, either alone or in combination with current targeted therapies. The appealing strength of such therapeutic option dwells in miRNAs’ ability to concurrently target multiple genes, frequently in the context of a specific network/pathway. This property allows miRNA-based therapy to be extremely efficient in regulating distinct biological processes relevant to normal and pathological cell homeostasis. The purpose of this review is to summarize the role of miRNAs in gastrointestinal carcinogenesis and their potential use as novel biomarkers and therapeutics.
Export Options
About this article
Cite this article as:
MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis, Current Drug Targets 2015; 16 (4) . https://dx.doi.org/10.2174/1389450116666141210091454
DOI https://dx.doi.org/10.2174/1389450116666141210091454 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis
Current Pharmaceutical Design Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Molecular Interplay between Platelets and the Vascular Wall in Thrombosis and Hemostasis
Current Vascular Pharmacology CIAPIN1 siRNA Inhibits Proliferation, Migration and Promotes Apoptosis of VSMCs by Regulating Bcl-2 and Bax
Current Neurovascular Research The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer
Current Pharmaceutical Design Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Anti-Helicobacter pylori Agents. An Update
Mini-Reviews in Medicinal Chemistry Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design